Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Fusen Pharmaceutical Co. Ltd. has announced the acceptance of its application by China’s National Medical Products Administration to launch ‘Enzalutamide Soft Capsules,’ a new treatment for prostate cancer. The drug, developed by a subsidiary of the company, is aimed at patients with non-metastatic and metastatic castration-resistant prostate cancer. This addition is set to expand the company’s anti-tumor therapy portfolio and offer more options for prostate cancer treatment.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.